Finasteride and Women: What the Label Itself Reports

Finasteride for women is prescribed off-label, discussed enthusiastically in forums, and sold nowhere legitimately without a prescriber. The most useful document about it is not a review or a study summary: it is the manufacturer's own label, which is free to read on DailyMed, and which contains three facts that change the conversation.

This page prints no dose, no strength recommendation and no schedule. Finasteride is prescription-only, its use in women is off-label, and those decisions belong to a prescriber who knows your history.

Fact one: the indication says men only

The label for Propecia, the finasteride product marketed for hair loss, states that it is indicated for the treatment of male pattern hair loss (androgenetic alopecia) "in MEN ONLY". The capitals are the label's, not ours. The version read for this page was revised 14 October 2024.

That does not make prescribing it to a woman improper. Off-label prescribing — using an approved medicine outside its approved indication — is legal, common and sometimes the right clinical decision. It does mean that no regulator has assessed this medicine for this use in this population, and that the prescriber carries that judgement.

Fact two: the trial in postmenopausal women did not show an effect

Here is the part that rarely survives the journey into a forum post. The label reports a study of 137 postmenopausal women — 67 on finasteride and 70 on placebo — over 12 months, in which effectiveness could not be demonstrated: there was no improvement in any measured outcome compared with placebo.

That is the manufacturer's own data, published on the manufacturer's own label. It is a single study, it is one population, and specialists point to different groups and different approaches where they believe there is a case. But anyone about to be prescribed finasteride for hair loss after menopause should know that this study exists and what it found, and it is not usually the first thing offered.

Fact three: pregnancy is a contraindication, and it extends to handling the tablets

The label states that finasteride use is contraindicated in women when they are or may potentially be pregnant, because of the risk to a male fetus. It goes further: women should not handle crushed or broken tablets when they are pregnant or may potentially be pregnant, because of the possibility of absorption.

That is a practical instruction with consequences at home as well as in the pharmacy — a household where someone is taking finasteride and someone else is or may become pregnant is a household where the tablets need handling accordingly. It is also the clearest possible answer to the question of whether finasteride is something to experiment with unsupervised. It is not.

Why it is still prescribed to some women

Dermatologists do prescribe 5-alpha-reductase inhibitors to women in particular circumstances, and a 2025 comprehensive review of drugs for alopecia in Expert Opinion on Drug Metabolism and Toxicology places finasteride among the treatments considered for non-scarring hair loss alongside minoxidil, JAK inhibitors and anti-androgens such as spironolactone — while emphasising individualised treatment and the need to weigh side effects including sexual dysfunction and liver enzyme changes.

The honest summary is that this is a decision made case by case by a specialist, on evidence that is much weaker in women than in men, with a hard contraindication attached to pregnancy. That is a very different thing from the confident "women take it too" you will read elsewhere.

Dutasteride, briefly

Dutasteride is a related medicine, also prescription-only, also off-label for hair loss in women, with less evidence again in this population. The same 2025 review groups it with the other pharmacological options for androgenetic alopecia and the same caution applies with more force: less studied, same category of risk, prescriber-only.

There is no version of this page that responsibly compares strengths or suggests one over the other. That comparison is the appointment.

What to ask if it is offered to you

• Why this rather than the route with randomised trials in women behind it?
• What is the plan for contraception while I take it, and for how long after?
• What are we measuring, and at what point do we stop if nothing changes?
• What monitoring, if any, do you want — and why?

Those four questions are free, and they will tell you a good deal about the quality of the service offering it. A service that cannot answer the second one should not be prescribing.

The route with the evidence, for comparison

Topical minoxidil is the only active ingredient approved over the counter for female pattern hair loss, and the trials behind it were run in women: 381 of them in a 48-week randomised placebo-controlled trial, with 5% beating placebo on all three primary measures. Our page on minoxidil for women, read off the label and the trials covers what that trial found and what the label warns about, including its own pregnancy sentence.

For the full picture, every hair-loss treatment for women, graded by what was tested in women puts finasteride in the order the evidence puts it — below topical minoxidil and below spironolactone for this population — rather than in the order enthusiasm puts it.

One thing this site will not do

It will not tell you what other people take. Dosage, strength and combination are the specific things a prescriber controls, and repeating them from a forum is how a medicine with a fetal-risk contraindication ends up in the wrong hands. If a page you are reading tells you how much to take, that is the page to close.